MediWound Ltd. - Ordinary Shares (MDWD)

Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers

Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time

Findings in Burns Journal confirm NexoBrid’s superiority over standard of care in pediatric patients with deep thermal burnsNexoBrid is approved for pediatric use in the U.S., E.U. and Japan

YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will present a corporate overview at the upcoming 45th Annual TD Cowen Health Care Conference, taking place in Boston, MA on Wednesday, March 5, 2025, at 11:50 AM ET. To listen to the live webcast of the presentation, please register here.

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual). The fireside chat, hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer, will take place on Wednesday, February 12, 2025 at 8:00 AM ET. To attend the virtual fireside chat, please register here.

YAVNE, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, January 8, 2025, at 10:00 AM ET. The event will focus on EscharEx®, an innovative biologic drug in late-stage clinical development for chronic wound debridement, including the upcoming Phase III VALUE study in venous leg ulcers (VLUs) and EscharEx’s commercial opportunity.

EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025

Conference Call and Webcast Scheduled for Tuesday, November 26, 2024, at 8:30 a.m. Eastern Time

Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes

YAVNE, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the 2024 Maxim Healthcare Virtual Summit. The fireside chat, hosted by Michael Okunewitch, Senior Biotechnology Analyst at Maxim, will take place on Wednesday, October 16, 2024, at 9:30 a.m. ET.

YAVNE, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research, on Tuesday, September 10, 2024 at 3:30 p.m. ET at the H.C. Wainwright 26th Annual Global Investment Conference.

Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages

MDWD stock results show that MediWound missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Completed Construction of New NexoBrid® Manufacturing Facility

NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients

Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time

Research Published in THE LANCET's eClinicalMedicineEscharEx® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue

Funds to be used for clinical development of EscharEx® to treat diabetic foot ulcers (DFUs)

Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment